Ocuphire Pharma Results

Track Record of Achieving Milestones Multiple Positive Data Readouts with Multiple Catalysts Ahead Positive Nyxol Phase 3 Data for RM (MIRA-2) 20211H 2022 Ocuphire PHARMA Positive Nyxol+LDP Phase 2 Data for Presbyopia (VEGA-1) Positive Nyxol Alone P2 Data for Presbyopia (VEGA-1) Positive Nyxol 2nd Phase 3 Data for RM (MIRA-3) Positive Nyxol Phase 3 Data for NVD (LYNX-1) Positive Nyxol Pediatric Data for RM (MIRA-4) 2H 2022 – 2023 Submit Nyxol NDA for RM Report APX3330 Phase 2b Data for DR/DME (ZETA-1) Initiate VEGA Phase 3 Presbyopia Program Potential Nyxol Approval and Commercialization Ongoing Partnering Discussions with Leading Ophthalmic Companies (including Europe and Asia) 8

View entire presentation